Hisamitsu Pharmaceutical concludes major ¥12.2bn share buyback program

Hisamitsu Pharmaceutical Co., Inc. announced the completion of its treasury stock acquisition program, which concluded on November 19, 2025. In the final phase, the company acquired 254,600 shares of its common stock between November 1 and November 19, 2025, for a total cost of ¥1,051,793,000. These acquisitions were executed through market purchases on the Tokyo Stock Exchange.

The completed program, approved by the board of directors on July 10, 2025, aimed to repurchase up to 3 million shares or a maximum of ¥15 billion between July 11 and December 31, 2025. Cumulatively, Hisamitsu Pharmaceutical acquired 3,000,000 shares, representing 4.09% of its outstanding shares (excluding treasury shares), at a total cost of ¥12,269,266,700.

The board's resolution allowed for acquisition through both off-auction own share repurchase transactions (ToSTNeT-3) and open market purchases on the Tokyo Stock Exchange. The successful completion marks a significant fulfillment of the company's commitment to shareholder returns.